Neurocrine Biosciences (NBIX) EBITDA Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | 842.00 |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 214.00 |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -963.00 |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 2,139.00 |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | -1,031.00 |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn | -46.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -46.00 |
| Mar 31, 2026 | 5,091.00 |
| Dec 31, 2025 | 109.00 |
| Sep 30, 2025 | 743.00 |
| Jun 30, 2025 | 671.00 |
| Mar 31, 2025 | 312.00 |
| Dec 31, 2024 | 3,426.00 |
| Sep 30, 2024 | 1,451.00 |
| Jun 30, 2024 | 290.00 |
| Mar 31, 2024 | 596.00 |
| Dec 31, 2023 | 21.00 |
| Sep 30, 2023 | 4,545.00 |
| Jun 30, 2023 | -907.00 |
| Mar 31, 2023 | -5,201.00 |
| Dec 31, 2022 | 511.00 |
| Sep 30, 2022 | -1,793.00 |
| Jun 30, 2022 | -428.00 |
| Mar 31, 2022 | 7,397.00 |
| Dec 31, 2021 | -2,820.00 |
| Sep 30, 2021 | -2,076.00 |